• MOUSUMI DAS Department of Pharmaceutical Technology, Division of Microbiology and Biotechnology, Jadavpur University, Kolkata, West Bengal, India.
  • BHASKAR DAS Department of Pharmaceutical Technology, Division of Microbiology and Biotechnology, Jadavpur University, Kolkata, West Bengal, India.
  • ARNAB DE Department of Pharmaceutical Technology, Division of Microbiology and Biotechnology, Jadavpur University, Kolkata, West Bengal, India.
  • SUBHASIS BANERJEE Department of Pharmaceutical Chemistry, Gupta College of Technological Sciences, Ashram More, Asansol, Kolkata - 713 301, West Bengal, India.
  • AMALESH SAMANTA Department of Pharmaceutical Technology, Division of Microbiology and Biotechnology, Jadavpur University, Kolkata, West Bengal, India.


Objective: A series of 5-substituted-4-amino-1, 2, 4-triazole-linked hydroxamic acid derivatives have been synthesized and explored in vitro to evaluate antibacterial and antifungal activities.

Methods: Different 5-phenyl group substituted-4-amino-1,2,4-triazole-3-thiol reacted with chlorine substituted hydroxamic acid to produce the desired compounds and characterized spectroscopically. Minimum inhibitory concentration (MIC), zone of inhibition (ZOI), growth kinetic studies, and scanning electron microscopy (SEM) were employed to elicit the antimicrobial efficacy of synthesized compounds against a wide range of bacterial and fungal strains.

Results: Compounds 6a, 6b, 6d, and 6k (MIC of 25 μg/ml) have been found to be more potent against Klebsiella pneumoniae, Bacillus cereus, Bacillus pumilus, Micrococcus luteus, and Pseudomonas aeruginosa, compounds 6a-6d, 6k, and 6l (MIC of 25–50 μg/ml) have shown potent antibacterial efficacy against Klebsiella pneumonia, P. aeruginosa, and Vibrio cholera compare to the standard drug amoxicillin (MIC of 60 μg/ml, 65 μg/ml, and 25 μg/ml, respectively). Screening for the antifungal activity revealed that the compounds were found to be most active against Candida albicans (6a, 6b, and 6l), Candida tropicalis (6b and 6d), and Aspergillus niger (6a, 6b, 6d, and 6j) with MIC of 15–25 μg/ml. Bacteriostatic and fungistatic effect of titled compounds was revealed from growth kinetics study.

Conclusion: Electron donating group at the 5-position of the 5-substituted-1,2,4-triazole-linked hydroxamic acid derivatives conferred the biological effectiveness of the synthesized compounds and also offer a therapeutically effective prototypical structure for further development of new chemical entities with superior antimicrobial activity.

Keywords: 1,2,4-triazole, Hydroxamic acid, Antibacterial, Antifungal.


1. Pisal P, Deodhar M, Kale A, Nigade G, Pawar S. Design, synthesis, docking studies and biological evaluation of 2-phenyl-3-(substituted benzo[d] thiazol-2-ylamino)-quinazoline-4(3h)-one derivativesas antimicrobial agents. Int J Pharm Pharm Sci 2018;10:57-61.
2. Gadhave PP, Dighe NS, Pattan SR, Deotarse P, Musmade DS, Shete RV. Current biological and synthetic profile of triazoles: A review. Ann Biol Res 2010;1:82-9.
3. Aoyama Y, Yoshida Y, Sato R. Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. II. Lanosterol metabolism by purified P-450(14)DM and by intact microsomes. J Biol Chem 1984;259:1661-6.
4. Kelly SL, Arnoldi A, Kelly DE. Molecular genetic analysis of azole antifungal mode of action. Biochem Soc Trans 1993;21:1034-8.
5. Groll AH, Lumb J. New developments in invasive fungal disease. Future Microbiol 2012;7:179-84.
6. Casalinuovo IA, Di Francesco P, Garaci E. Fluconazole resistance in Candida albicans: A review of mechanisms. Eur Rev Med Pharmacol Sci 2004;8:69-77.
7. Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin Investig Drugs 2000;9:593-605.
8. Bairam R, Srinivasa MM, Sreekanth S. Synthesis, characterization, biological evaluation and docking of some novel substituted 1, 3-thiazine derivatives. Int J Pharm Pharm Sci 2017;9:233-42.
9. Aggarwal N, Kumar R, Srivastva C, Dureja P, Khurana JM. Synthesis of nalidixic acid based hydrazones as novel pesticides. J Agric Food Chem 2010;58:3056-61.
10. Palekar VS, Damle AJ, Shukla SR. Synthesis and antibacterial activity of some novel bis-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and bis-4-thiazolidinone derivatives from terephthalic dihydrazide. Eur J Med Chem 2009;44:5112-6.
11. Jain AK, Sharma S, Vaidya A, Ravichandran V, Agrawal RK. 1,3,4-thiadiazole and its derivatives: A review on recent progress in biological activities. Chem Biol Drug Des 2013;81:557-76.
12. Prasad DJ, Ashok M, Karegoudar P, Poojary B, Holla BS, Kumari NS, et al. Synthesis and antimicrobial activities of some new triazolothiadiazoles bearing 4-methylthiobenzyl moiety. Eur J Med Chem 2009;44:551-7.
13. Foroumadi A, Mansouri S, Kiani Z, Rahmani A. Synthesis and in vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolones. Eur J Med Chem 2003;38:851-4.
14. Ram VJ, Mishra L, Pandey NH, Kushwaha DS, Pieters LA, Vlietinck AJ. Bis heterocycles as potential chemotherapeutic agents. X. Synthesis of bis (4-arylthiosemicarbazido)-, bis (2-arylamino-1, 3, 4-thiadiazol-5-yl) and bis (4-aryl-1, 2, 4-triazolin-3-thione-5-yl) pentanes and related compounds. J Heterocycl Chem 1990;27:351-5.
15. Ergenç N, Ilhan E, Otük G. Synthesis and biological activity of 1,4-disubstituted thiosemicarbazides and their 1,2,4-triazole-5-thione derivatives. Pharmazie 1992;47:59-60.
16. Ram VJ, Pandey HN. Synthesis of 5-membered heterocycles and related compounds. Chem Pharm Bull (Tokyo) 1974;22:2778-83.
17. Reddy KR, Mogilaiah K, Swamy B, Sreenivasulu B. Substituted 1, 8-naphthyridines. Part 11. Synthesis of some 1, 8-naphthyridinylthiosemicarbazides,-triazoles and-thiadiazoles. Cheminformation 1990;21:178.
18. Hiremath SP, Sonar VN, Sekhar KR, Purohit MG. Synthesis of oxadiazolyl-, thiadiazolyl-and triazolylindoles and indolylthiazolidinones. Cheminformation 1989;20:148.
19. Kalyoncuo?lu N, Rollas S, Sür-Altiner D, Ye?eno?lu Y, An? O. 1-[p-(Benzoylamino)benzoyl]-4-substituted thiosemicarbazides: Synthesis and antibacterial and antifungal activities. Pharmazie 1992;47:796-7.
20. Sarigol D, Uzgoren-Baran A, Tel BC, Somuncuoglu EI, Kazkayasi I, Ozadali-Sari K, et al. Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies. Bioorg Med Chem 2015;23:2518-28.
21. Yehye WA, Abdul Rahman N, Saad O, Ariffin A, Abd Hamid SB, Alhadi AA, et al. Rational design and synthesis of new, high efficiency, multipotent schiff base-1,2,4-triazole antioxidants bearing butylated hydroxytoluene moieties. Molecules 2016;21:847.
22. Sztanke K, Tuzimski T, Rzymowska J, Pasternak K, Kandefer-Szersze? M. Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. Eur J Med Chem 2008;43:404-19.
23. Haber J. Present status and perspectives on antimycotics with systemic effects. Cas Lek Cesk 2001;140:596-604.
24. Adams WJ, Bombardt PA, Code RA. Absorption of triazolam from pelleted drug–diet mixtures by the mouse: Quantitation of ? hydroxytriazolam in urine. J Pharm Sci 1983;72:1185-9.
25. Sidwell RW, Allen LB, Huffman JH, Witkowski JT, Simon LN. Effect of l-?-D-ribofuranosyl-l, 2, 4-triazole-3-carboxamide (Ribavirin) on friend leukemia virus infections in mice. Proc Soc Exp Biol Med 1975;148:854-8.
26. Indiani C, Santoni E, Becucci M, Boffi A, Fukuyama K, Smulevich G. New insight into the peroxidase? hydroxamic acid interaction revealed by the combination of spectroscopic and crystallographic studies. Biochemistry 2003;42:14066-74.
27. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
28. Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, et al. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J Med Chem 2006;49:6046-56.
29. Hanessian S, Parthasarathy S, Mauduit M, Payza K. The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity. J Med Chem 2003;46:34-48.
30. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6.
31. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
32. Odake S, Morikawa T, Tsuchiya M, Imamura L, Kobashi K. Inhibition of Helicobacter pylori urease activity by hydroxamic acid derivatives. Biol Pharm Bull 1994;17:1329-32.
33. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735-76.
34. Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, et al. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem 2002;45:219-32.
35. Nandy P, Lien EJ, Avramis VI. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: Drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis. Anticancer Res 1999;19:1625-33.
36. Kerdesky FA, Schmidt SP, Holms JH, Dyer RD, Carter GW, Brooks DW, et al. Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid analogues. J Med Chem 1987;30:1177-86.
37. Cocea E, Grigoras M, Tutoveanu M. Polimeri analogi, nota V: Acizi polihidraxamici si hidrazide copolimere. Bul Inst Polit Iasi 1965;11:159 62.
38. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5.
39. McFarland J. The nephelometer: An instrument for estimating the number of bacteria in suspensions used for calculating the opsonic index and for vaccines. JAMA 1907;49:1176-8.
40. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard M2-A9. 9th ed., Vol. 26. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
41. Bantar C, Schell C, Posse G, Limansky A, Ballerini V, Mobilia L. Comparative time–kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii. Diagn Microbiol Infect Dis 2008;61:309-14.
42. Kundu S, Abdullah MF, Das A, Basu A, Halder A, Das M, et al. Antifungal ouzo nanoparticles from guar gum propionate. RSC Adv 2016;6:106563-71.
43. Bandyopadhyay N, Zhu M, Lu L, Mitra D, Das M, Das P, et al. Synthesis, structure, spectral characterization, electrochemistry and evaluation of antibacterial potentiality of a novel oxime-based palladium(II) compound. Eur J Med Chem 2015;89:59-66.
44. Trott O, Olson AJ. AutoDock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-61.
45. Podust LM, Poulos TL, Waterman MR. Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A 2001;98:3068-73.
46. Rose PW, Bi C, Bluhm WF, Christie CH, Dimitropoulos D, Dutta S, et al. The RCSB protein data bank: New resources for research and education. Nucleic Acids Res 2013;41:D475-82.
47. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR, et al. Open babel: An open chemical toolbox. J Cheminform 2011;3:33.
48. Reid JR, Heindel ND. Improved syntheses of 5-substituted-4-amino-3-mercapto-(4H)-1, 2, 4-triazoles. J Heterocycl Chem 1976;13:925-26.
49. Hase J, Kobashi K, Kawaguchi N, Sakamoto K. Antimicrobial activity of hydroxamic acids. Chem Pharm Bull (Tokyo) 1971;19:363-8.
50. Rossello A, Bertini S, Lapucci A, Macchia M, Martinelli A, Rapposelli S, et al. Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem 2002;45:4903 12.
17 Views | 27 Downloads
How to Cite
Original Article(s)